2022
DOI: 10.1177/23247096221086453
|View full text |Cite
|
Sign up to set email alerts
|

Pulmonary Tumor Embolism and Pulmonary Tumor Thrombotic Microangiopathy Causing Rapidly Progressive Respiratory Failure: A Case Series

Abstract: Pulmonary tumor embolism (PTE) and pulmonary tumor thrombotic microangiopathy (PTTM) are rare etiologies for rapidly progressive dyspnea in the setting of undiagnosed metastatic cancer. They occur most frequently in association with adenocarcinomas, with PTE being most frequently associated with hepatocellular carcinoma and PTTM being most commonly reported with gastric adenocarcinoma. Pulmonary tumor embolism and PTTM appear to be a disease spectrum where PTTM represents an advanced form of PTE. Pulmonary tum… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 25 publications
0
7
0
Order By: Relevance
“…Concerns are raised that tumoural PH is largely underdiagnosed as the clinical course often results in a rapid deterioration and fatal outcome before diagnostics are completed. 2 Post mortem studies have documented tumoural emboli in pulmonary microcirculation in ∼26% of patients with a solid tumour, markedly associated with adenocarcinoma, 3–5 whereas PTTM has been observed in ∼3.3% of patients with extrathoracic malignancies with highest frequency (26%) in gastric carcinomas. When PTTM is suspected ante mortem and RHC is performed, a blood sample of the pulmonary artery can be analysed for tumour cells to further confirm the diagnosis.…”
Section: Discussionmentioning
confidence: 99%
“…Concerns are raised that tumoural PH is largely underdiagnosed as the clinical course often results in a rapid deterioration and fatal outcome before diagnostics are completed. 2 Post mortem studies have documented tumoural emboli in pulmonary microcirculation in ∼26% of patients with a solid tumour, markedly associated with adenocarcinoma, 3–5 whereas PTTM has been observed in ∼3.3% of patients with extrathoracic malignancies with highest frequency (26%) in gastric carcinomas. When PTTM is suspected ante mortem and RHC is performed, a blood sample of the pulmonary artery can be analysed for tumour cells to further confirm the diagnosis.…”
Section: Discussionmentioning
confidence: 99%
“…Evidence-based findings supporting the use of anticoagulants, antibiotics, or steroid therapy in this entity are lacking. 9 Moreover, although both PTE and chronic thromboembolic pulmonary hypertension are classified as group 4 pulmonary hypertension, PTE is not considered amenable to standard pulmonary hypertension therapies because of its distinct pathophysiology. Unfortunately, PTE is often an end-stage presentation of advanced cancer, which commonly displays a rapid clinical course once respiratory symptoms ensue.…”
Section: Discussionmentioning
confidence: 99%
“…An invasive technique for the diagnosis of TE is represented by cytological examination of blood aspirated from a wedged pulmonary artery catheter, which could detect the tumor cells. The sensitivity of this technique is 80% to 88%, and specificity is 82 to 94% [ 94 ].…”
Section: Tumor Embolismmentioning
confidence: 99%
“…There is no specific treatment available for TE. Specific therapeutic measures for the primary tumor associated with treatment for pulmonary hypertension are indicated [ 94 ].…”
Section: Tumor Embolismmentioning
confidence: 99%